Attana

0,01 SEK

+28,57 %

Mindre end 1K følgere

ATANA

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+28,57 %

+28,57 %

0,00 %

-10,00 %

-64,00 %

+80,00 %

-92,45 %

-98,84 %

-94,15 %

Attana conducts research and development of pharmaceuticals. The company specializes in biological interaction characterization, which is used for analysis in the development of new drugs. The company's patented solutions are used in the study of binding properties and macrostructures in cells, proteins, viruses and bacteria. Operations are primarily in the Nordic region and Europe. The company was founded in 2002 and is headquartered in Stockholm.

Markedsværdi

23,23 mio. SEK

Aktieomsætning

521,14 t SEK

Omsætning

4,1 mio.

EBIT %

-244,15 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

27.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse30.4.2024, 09.45

BioInvent evaluating Attana Technology

Pressemeddelelse25.4.2024, 13.43

Attana enters the third year of a five-year service and support contract with a leading health institute in the US

Pressemeddelelse1.4.2024, 09.29

New paper using Attana tecnology to understand how viruses enter human cells

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse5.3.2024, 09.44

Attana: One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k

Pressemeddelelse13.2.2024, 14.14

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

Pressemeddelelse23.1.2024, 12.42

New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials

Pressemeddelelse20.12.2023, 07.30

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases

Pressemeddelelse18.12.2023, 07.30

Attana: Biosensors to characterize immune response to bacterial diseases

Pressemeddelelse5.12.2023, 10.15

Attana and Linnaeus University have published the first part of the science behind immunity profiles

Pressemeddelelse4.12.2023, 08.56

Attana: Breakthrough order with new customer in the USA

Pressemeddelelse23.11.2023, 07.28

Attana: Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.

Pressemeddelelse20.11.2023, 10.55

A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2

Pressemeddelelse15.11.2023, 13.51

Attana: Robust QCM-Based Sensing and Assay Formats in Commercialized Systems

Pressemeddelelse4.10.2023, 15.03

Attana: Dear shareholders and valuable followers,

Pressemeddelelse26.9.2023, 09.33

New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.

Pressemeddelelse6.9.2023, 13.14

New publication from National University of Singapore using Attana Technology to study Immune Response from Tuberculosis Exposed Healthy Individuals

Pressemeddelelse28.8.2023, 15.32

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

Pressemeddelelse30.5.2023, 08.41

Education in advanced Attana cell-based assays and practical hands-on training in maintenance.

Pressemeddelelse23.5.2023, 07.23

Attana prolongs service and support contract with European client

Pressemeddelelse23.5.2023, 06.06

Attanas immunity profiles depicted in the Life Science section of yesterday's Dagens Nyheter

Forumopdateringer

Attanalle 5 v pituinen sopimus USA:han, sopimuksella on positiivinen vaikutus kassavirtaan sopimuskauden aikana. Alkuvuodesta tuli uutinen yhteistyö- ja tutkimussopimuksesta Yhdysvaltalaisen yliopistosairaalan kanssa. Pienempiä uutisia on tullut myös uusista julkaistuista tutkimuksista...

25.4.2022, 13.58

af Mikael Kahn

4

“Tag dine tab hurtigt” er en ret god talemåde, når det gælder denne type selskaber.

9.12.2023, 12.32

af Warren Noutopöytätarjoilu

1

Der er en emission på vej. Jeg overvejer, om jeg endelig skal realisere tabet på 95 %, eller om jeg stadig skal finansiere det her lækkende skib. Er der andre, der stadig er med ombord?

8.12.2023, 12.14

af III21

1

News Powered by Cision Attana plans to move production of consumables to AroCell Attana can today announce that the company has begun a discussion about moving production of

5.5.2022, 16.47

af PP2020

1

Denne multibagger har vist multibagget den forkerte vej, så der kun er 1/20 af værdien tilbage.

9.12.2023, 11.10

af Tunturisusi

0

En lille portion, der ligger og bliver sur i bunden af porteføljen, og jeg er ikke ligefrem begejstret for at deltage i emissionen. Må indrømme, at jeg slet ikke har fulgt med i firmaets gøren og laden på det seneste.

9.12.2023, 08.13

af ghoul

0

Börskollen Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB Pressmeddelande i aktien Attana. Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB. Taloudellinen katsaus (ei yhtiön tilintarkastajan tilintarkastama): Liikevaihto 3,1 (1,1) miljoonaa SEK...

6.5.2022, 06.11

af Tume

0

Besøg forummet

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.